Private Insurers Say No To Aduhelm // Chip Shortage Scammers // Ted Rossman of Bankrate - 7/14 (Hour 2)

(0:40) - The FDA's recent approval of Biogen's Alzheimer's drug (Aduhelm) remains quite controversial. Now, private insurers are saying that they will not cover the drug despite the approval.(12:28) - The semiconductor shortage rolls on, and predictably, there are scammers looking to capitalize on the situation. Many fraudsters are advertising fake parts in order to take advantage of desperate companies.(22:46) - Child tax credit payments are slated to be received by families for the first time this week. However, these payments will not necessarily be going towards the children of these families.(30:31) - Ted Rossman of Bankrate.com joined the show to discuss a highly debated topic: tipping. Which generation has the best tippers, and just how much do people tip?